ArticleMolecular therapy. Oncology2026

A measles virus encoding a CD19/CD3 bispecific T cell engager shows enhanced preclinical anti-BCP-ALL efficacy without significant toxicity.

Sabine Heinze et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.